Johnson & Johnson coronavirus vaccine targeted to be launched in early 2021
Johnson & Johnson said that it has selected a lead coronavirus vaccine candidate from constructs it has been working on since the start of this ... Read More
Janssen to acquire skin disease drug candidate bermekimab from XBiotech
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational ... Read More
Janssen bags Stelara FDA approval for ulcerative colitis treatment
Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged approval from the US Food and Drug ... Read More
Janssen bags Xarelto FDA approval to prevent blood clots in acutely ill patients
Xarelto FDA approval : The Janssen Pharmaceutical Companies of Johnson & Johnson has secured approval from the US Food and Drug Administration (FDA) for Xarelto ... Read More
Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint
Ponesimod OPTIMUM trial results : Johnson & Johnson's Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to ... Read More
Guselkumab meets primary endpoints in phase 3 psoriatic arthritis program
Johnson & Johnson’s Janssen Pharmaceutical said that its IL-23 p19 inhibitor TREMFYA (guselkumab) met the primary endpoints of American College of Rheumatology 20% improvement (ACR20) ... Read More
Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has received approval from the US Food and Drug Administration (FDA) for its combination treatment of IMBRUVICA ... Read More